Page last updated: 2024-11-11

4-methylene-2-octyl-5-oxofuran-3-carboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-methylene-2-octyl-5-oxofuran-3-carboxylic acid: an anorectic fatty acid synthase inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(2R,3S)-C75 : A 4-methylidene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid that has 2R,3S-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9881506
CHEMBL ID449993
CHEBI ID180531
CHEBI ID191400
SCHEMBL ID3007085
MeSH IDM0360876

Synonyms (44)

Synonym
CHEBI:180531
3-furancarboxylic acid, tetrahydro-4-methylene-2-octyl-5-oxo-, (2r,3s)-rel-
(2r,3s)-4-methylidene-2-octyl-5-oxooxolane-3-carboxylic acid
3-carboxy-4-octyl-2-methylenebutyrolactone
c75 cpd
4-methylene-2-octyl-5-oxofuran-3-carboxylic acid
AC-11808
(trans)-4-methylene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid
bdbm50256128
191282-48-1
CHEMBL449993 ,
CHEBI:191400
(2r,3s)-4-methylene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid
(+)-c75
(2r,3s)-4-methylidene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid
(2r,3s)-c75
trans-tetrahydro-3-methylene-2-oxo-5-n-octyl-4-furancarboxylic acid
AKOS015960616
S8915
SCHEMBL3007085
c75 trans
trans-c75
HMS3649D16
fas inhibitor, c75
(2r,3s)-tetrahydro-4-methylene-2-octyl-5-oxo-3-furancarboxylic acid
c75 (trans)
c75 (racemic)
J-012362
1234694-20-2
(+-)-c 75
trans-4-methylene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid
EX-A3805
(+)-trans-c75
sr-01000946704
SR-01000946704-1
BCP11074
( inverted exclamation marka)-c75;c75;c-75;c 75;trans-4-carboxy-5-octyl-3-methylenebutyrolactone
(+/-)-c75
BS-48883
tetrahydro-4-methylene-2s-octyl-5-oxo-3r-furancarboxylic acid
( inverted exclamation marka)-c75( inverted exclamation marka)-c75
BP-25387
()-c75
E85140

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"Because C75 causes an effect that is shorter in duration than expected, modification of the current weekly dosing regimen should be considered."( FDG-PET for pharmacodynamic assessment of the fatty acid synthase inhibitor C75 in an experimental model of lung cancer.
Alvey, S; Gabrielson, E; Gabrielson, K; Hagemann, RL; Kuhajda, FP; Lee, JS; Orita, H; Pomper, MG, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
gamma-lactoneA lactone having a five-membered lactone ring.
4-methylidene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acidA tetrahydrofuranone that is tetrahydrofuran substituted by octyl, carboxy, methylidene, and oxo groups at positions 2, 3, 4 and 5, respectively.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty acid synthaseGallus gallus (chicken)IC50 (µMol)80.00006.15007.63008.3700AID697061
Fatty acid synthase Rattus norvegicus (Norway rat)IC50 (µMol)15.53000.05000.05000.0500AID370705; AID415920
Fatty acid synthaseHomo sapiens (human)IC50 (µMol)45.71500.00772.46245.8000AID697039; AID697055
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (15)

Processvia Protein(s)Taxonomy
lactate metabolic processFatty acid synthaseGallus gallus (chicken)
fatty acid biosynthetic processFatty acid synthaseGallus gallus (chicken)
positive regulation of appetiteFatty acid synthaseGallus gallus (chicken)
osteoblast differentiationFatty acid synthaseHomo sapiens (human)
glandular epithelial cell developmentFatty acid synthaseHomo sapiens (human)
fatty acid metabolic processFatty acid synthaseHomo sapiens (human)
fatty acid biosynthetic processFatty acid synthaseHomo sapiens (human)
inflammatory responseFatty acid synthaseHomo sapiens (human)
ether lipid biosynthetic processFatty acid synthaseHomo sapiens (human)
neutrophil differentiationFatty acid synthaseHomo sapiens (human)
monocyte differentiationFatty acid synthaseHomo sapiens (human)
mammary gland developmentFatty acid synthaseHomo sapiens (human)
modulation by host of viral processFatty acid synthaseHomo sapiens (human)
cellular response to interleukin-4Fatty acid synthaseHomo sapiens (human)
establishment of endothelial intestinal barrierFatty acid synthaseHomo sapiens (human)
fatty-acyl-CoA biosynthetic processFatty acid synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
single-stranded DNA bindingFatty acid synthaseGallus gallus (chicken)
fatty acid synthase activityFatty acid synthaseGallus gallus (chicken)
[acyl-carrier-protein] S-acetyltransferase activityFatty acid synthaseGallus gallus (chicken)
[acyl-carrier-protein] S-malonyltransferase activityFatty acid synthaseGallus gallus (chicken)
3-oxoacyl-[acyl-carrier-protein] synthase activityFatty acid synthaseGallus gallus (chicken)
3-oxoacyl-[acyl-carrier-protein] reductase (NADPH) activityFatty acid synthaseGallus gallus (chicken)
(3R)-3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseGallus gallus (chicken)
(3R)-3-hydroxymyristoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseGallus gallus (chicken)
(3R)-3-hydroxydecanoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseGallus gallus (chicken)
fatty acyl-[ACP] hydrolase activityFatty acid synthaseGallus gallus (chicken)
phosphopantetheine bindingFatty acid synthaseGallus gallus (chicken)
(3R)-3-hydroxybutanoyl-[acyl-carrier-protein] hydratase activityFatty acid synthaseGallus gallus (chicken)
(3R)-3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseGallus gallus (chicken)
enoyl-[acyl-carrier-protein] reductase (NADPH) activityFatty acid synthaseGallus gallus (chicken)
RNA bindingFatty acid synthaseHomo sapiens (human)
[acyl-carrier-protein] S-acetyltransferase activityFatty acid synthaseHomo sapiens (human)
[acyl-carrier-protein] S-malonyltransferase activityFatty acid synthaseHomo sapiens (human)
3-oxoacyl-[acyl-carrier-protein] synthase activityFatty acid synthaseHomo sapiens (human)
3-oxoacyl-[acyl-carrier-protein] reductase (NADPH) activityFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseHomo sapiens (human)
protein bindingFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxymyristoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxydecanoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseHomo sapiens (human)
fatty acyl-[ACP] hydrolase activityFatty acid synthaseHomo sapiens (human)
phosphopantetheine bindingFatty acid synthaseHomo sapiens (human)
cadherin bindingFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxybutanoyl-[acyl-carrier-protein] hydratase activityFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseHomo sapiens (human)
enoyl-[acyl-carrier-protein] reductase (NADPH) activityFatty acid synthaseHomo sapiens (human)
fatty acid synthase activityFatty acid synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
cytoplasmFatty acid synthaseGallus gallus (chicken)
cytosolFatty acid synthase Rattus norvegicus (Norway rat)
Golgi apparatusFatty acid synthaseHomo sapiens (human)
cytosolFatty acid synthaseHomo sapiens (human)
plasma membraneFatty acid synthaseHomo sapiens (human)
membraneFatty acid synthaseHomo sapiens (human)
melanosomeFatty acid synthaseHomo sapiens (human)
glycogen granuleFatty acid synthaseHomo sapiens (human)
extracellular exosomeFatty acid synthaseHomo sapiens (human)
cytoplasmFatty acid synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID719680Increase in energy production in DIO mouse at 15 mg/kg, ip administered single dose2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID415920Inhibition of rat liver FAS by Coomassie blue staining2009Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5
Novel fatty acid synthase (FAS) inhibitors: design, synthesis, biological evaluation, and molecular docking studies.
AID370704Therapeutic index, ratio of TC50 for HLF to IC50 for Sprague-Dawley rat liver fatty acid synthase2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
1-Oxo-3-substitute-isothiochroman-4-carboxylic acid compounds: synthesis and biological activities of FAS inhibition.
AID645241Cytotoxicity against monkey MA104 cells after 24 hrs2012European journal of medicinal chemistry, Apr, Volume: 50Novel triacsin C analogs as potential antivirals against rotavirus infections.
AID719693Increase in liver CPT1 activity expressed in yeast mitochondrial extracts2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID683043Toxicity against C57BL/6J mouse assessed as signs of suffering at 30 mg/kg, ip administered as single dose measured after 24 hrs2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
New synthetic inhibitors of fatty acid synthase with anticancer activity.
AID645239Antiviral activity against Rotavirus SA11 in MA104 cells assessed as inhibition of viral replication after 24 hrs by immunofluorescent assay and Western blotting analysis2012European journal of medicinal chemistry, Apr, Volume: 50Novel triacsin C analogs as potential antivirals against rotavirus infections.
AID719690Increase in CPT1 activity in rat hepatocytes using [3H]carnitine by radiometric assay2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719691Increase in palmitate oxidation rat hepatocytes a at 80 uM2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID498457Inhibition of AMPK in zebrafish assessed as embryonic axis dorsalization at 400 uM treated at 3 hrs post-fertilization measured at 48 hrs2008Nature chemical biology, Jan, Volume: 4, Issue:1
Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism.
AID719671Inhibition of rat FAO2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID415922Cytotoxicity against human HLF by MTT assay2009Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5
Novel fatty acid synthase (FAS) inhibitors: design, synthesis, biological evaluation, and molecular docking studies.
AID415923Therapeutic index, ratio of TC50 for human HLF to IC50 for rat liver FAS2009Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5
Novel fatty acid synthase (FAS) inhibitors: design, synthesis, biological evaluation, and molecular docking studies.
AID498458Inhibition of AMPK in zebrafish assessed as embryonic axis dorsalization at 200 uM treated at 3 hrs post-fertilization measured at 48 hrs2008Nature chemical biology, Jan, Volume: 4, Issue:1
Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism.
AID498459Inhibition of AMPK in zebrafish assessed as embryonic axis dorsalization at 100 uM treated at 3 hrs post-fertilization measured at 48 hrs2008Nature chemical biology, Jan, Volume: 4, Issue:1
Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism.
AID697039Inhibition of human recombinant FASN thioesterase domain2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
The lipogenesis pathway as a cancer target.
AID683042Toxicity against C57BL/6J mouse assessed as weight loss at 30 mg/kg, ip administered as single dose measured after 24 hrs2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
New synthetic inhibitors of fatty acid synthase with anticancer activity.
AID498461Inhibition of AMPK in zebrafish assessed as embryonic axis dorsalization at 20 uM treated at 3 hrs post-fertilization measured at 48 hrs2008Nature chemical biology, Jan, Volume: 4, Issue:1
Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism.
AID719672Cytotoxicity in human KB cells2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID697055Inhibition of FASN in human A375 cells2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
The lipogenesis pathway as a cancer target.
AID498464Toxicity in zebrafish assessed as survivability at 4 to 400 uM treated at 3 hrs post-fertilization measured at 48 hrs2008Nature chemical biology, Jan, Volume: 4, Issue:1
Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism.
AID498460Inhibition of AMPK in zebrafish assessed as embryonic axis dorsalization at 40 uM treated at 3 hrs post-fertilization measured at 48 hrs2008Nature chemical biology, Jan, Volume: 4, Issue:1
Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism.
AID370705Inhibition of Sprague-Dawley rat liver fatty acid synthase2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
1-Oxo-3-substitute-isothiochroman-4-carboxylic acid compounds: synthesis and biological activities of FAS inhibition.
AID697061Inhibition of chicken liver FASN ketoreductase activity2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
The lipogenesis pathway as a cancer target.
AID498462Inhibition of AMPK in zebrafish assessed as embryonic axis dorsalization at 4 uM treated at 3 hrs post-fertilization measured at 48 hrs2008Nature chemical biology, Jan, Volume: 4, Issue:1
Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism.
AID370703Cytotoxicity against HLF by MTT assay2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
1-Oxo-3-substitute-isothiochroman-4-carboxylic acid compounds: synthesis and biological activities of FAS inhibition.
AID719673Inhibition of human FAO2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719679Induction of weight loss in DIO mouse at 15 mg/kg, ip administered single dose measured 20 hrs post dose (Rvb = 2 %)2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719692Increase in muscle CPT1 activity expressed in yeast mitochondrial extracts2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (107)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's65 (60.75)29.6817
2010's36 (33.64)24.3611
2020's6 (5.61)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.66 (24.57)
Research Supply Index4.68 (2.92)
Research Growth Index6.34 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (2.80%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other104 (97.20%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]